Diacerein for osteoarthritis

Area of Science:

• Rheumatology
• Pharmacology
• Clinical Trials

Background:

• Osteoarthritis (OA) is a prevalent musculoskeletal condition with no definitive treatment to halt progression.
• Diacerein, an interleukin-1 inhibitor, is investigated for its potential symptom-modifying and disease-modifying effects in OA.
• This is an updated Cochrane review assessing diacerein's efficacy and safety.

Purpose of the Study:

• To evaluate the benefits and harms of diacerein for OA treatment.
• To compare diacerein against placebo and other active OA interventions like NSAIDs.

Main Methods:

• Systematic review of randomized and quasi-randomized controlled trials.
• Searches conducted across multiple databases (CENTRAL, MEDLINE, EMBASE, LILACS) up to March 2013.
• Data abstraction and quality assessment using Cochrane risk of bias tool and GRADE approach.

Main Results:

• Low-quality evidence suggests a minimal pain reduction with diacerein (9% decrease) but no significant improvement in physical function.
• A small benefit in slowing knee/hip joint space narrowing was observed, but its clinical relevance is questionable.
• Diarrhea was a frequent adverse event, occurring in 24% more patients on diacerein, with a number needed to treat for harm of 4.

Conclusions:

• Diacerein provides minimal symptomatic benefit for OA pain and questionable structural benefit.
• Diarrhea is a significant adverse effect, leading to recommendations for suspension of diacerein marketing authorization in Europe.
• Consult EMA for the latest recommendations on diacerein use due to safety concerns.